Literature DB >> 1520597

Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data.

T S Maughan1, R Ward, I Dennis, D J Honess, P Workman, N M Bleehen.   

Abstract

Flavone acetic acid (FAA) showed impressive effects against murine solid tumours but no activity in clinical studies. The mechanism of action in mice may involve damage to tumour vasculature or immunomodulation, and these effects may be species-specific. Alternatively, concentrations of FAA achieved in mouse tumours may be higher than in human tumours. It is important to resolve this issue since it raises important questions about the relevance of in vitro versus in vivo tumour screens and the development of FAA analogues. As part of a Cancer Research Campaign Phase II study of metastatic melanoma in which 8.4 g m-2 FAA was given as a 6 h infusion, six tumour biopsies were obtained from four patients. FAA tumour concentrations were determined by HPLC and compared with subcutaneous murine solid tumours within the same analytical laboratory. Tumour/plasma percentages (range 26-61%; mean +/- SD, 43.9 +/- 11.4%) were similar to those in mice, as was the area under the curve (AUC) extrapolated to infinity and the AUC above the putative activity threshold of 100 micrograms ml-1. We conclude that the exposure of drug-refractory human melanoma tissue to FAA was comparable to that of sensitive mouse tumours. This suggests that reduced penetration of FAA into human tumours is unlikely to explain the lack of antitumour activity observed in clinical studies and that differences in mechanism of action are predominant.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1520597      PMCID: PMC1977940          DOI: 10.1038/bjc.1992.317

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Regional blood flow by fractional distribution of indicators.

Authors:  L A SAPIRSTEIN
Journal:  Am J Physiol       Date:  1958-04

2.  Flavone acetic acid: a nonlinear pharmacokinetic model.

Authors:  A Gouyette; D J Kerr; S B Kaye; A Setanoians; J Cassidy; C Bradley; G Forrest; M Soukop
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Blood flow failure as a major determinant in the antitumor action of flavone acetic acid.

Authors:  L J Zwi; B C Baguley; J B Gavin; W R Wilson
Journal:  J Natl Cancer Inst       Date:  1989-07-05       Impact factor: 13.506

4.  Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect.

Authors:  G J Finlay; G P Smith; L M Fray; B C Baguley
Journal:  J Natl Cancer Inst       Date:  1988-04-20       Impact factor: 13.506

5.  Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice.

Authors:  G G Chabot; M C Bissery; T H Corbett; K Rutkowski; L H Baker
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors.

Authors:  D S Zaharko; C K Grieshaber; J Plowman; J C Cradock
Journal:  Cancer Treat Rep       Date:  1986-12

7.  Phase I and pharmacokinetic study of flavone acetic acid.

Authors:  D J Kerr; S B Kaye; J Cassidy; C Bradley; E M Rankin; L Adams; A Setanoians; T Young; G Forrest; M Soukop
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

8.  Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer.

Authors:  R H Wiltrout; M R Boyd; T C Back; R R Salup; J A Arthur; R L Hornung
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

9.  Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.

Authors:  D J Kerr; T Maughan; E Newlands; G Rustin; N M Bleehen; C Lewis; S B Kaye
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

10.  Flavone acetic acid--an interesting novel therapeutic agent or just another disappointment?

Authors:  M C Bibby
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.